ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: Sep 29, 2014 | Print This Page

Get more stock ratings by Louis Navellier

(MAXY)

Rating: Volatility:
Total Grade: Industry:
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Maxygen, Inc., a biopharmaceutical company, engages in developing various products in the field of human therapeutics in North America. It focuses on the development of MAXY-G34 product candidate, a granulocyte colony stimulating factor, for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome. The company was founded in 1996 and is headquartered in San Mateo, California.

Recent News: